4d agoInvesting.com Analyst RatingsBULLISH 61Analyst
H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy
H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy
Archived explainer. For the current picture see today's INBX page.
Why Is INHIBRX BIOSCIENCES (INBX) Stock Up Today?
By the Top Tier Newswire AI Desk · September 9, 2026 at 9:42 AM ET · reviewed against 9 wire stories
INHIBRX BIOSCIENCES (INBX) is up +5.72% in the latest session. Our newswire has captured 9 stories on INBX across 8 sources in the last 36 hours, with AI sentiment reading bullish (avg 68/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
INBX stock is up 5.72% at $120.88 as of the latest trade, driven by positive Phase 2 data for its cancer therapy INBRX-106. The drug combination showed higher response rates in head and neck cancer trials, with the CEO and two directors buying shares on the same day the data was released.
What Happened
Inhibrx Biosciences announced strong Phase 2 results for INBRX-106 in combination with pembrolizumab, showing a 48.3% clinical overall response rate compared to 26.5% for monotherapy. The data was disclosed in a SEC Form 8-K filed on September 8, 2026, and the company is set to present the findings in a webcast. H.C. Wainwright reiterated a Buy rating for the stock, while Seeking Alpha highlighted the therapy’s outperformance of Merck’s Keytruda in the trial. The stock opened with a 2.7% gap up at $117.38, reflecting the market's positive reaction to the news. The CEO and two directors each made purchases on September 8, adding to the momentum.
What The Data Shows
The stock has moved -9.4% over the past eight sessions, from $123.93 to $112.28, but has now surged to a new 52-week high. The session opened at $117.38 and reached a high of $123.69 before settling near $121.40. The volume so far is 0.0M shares, which is below the 3-month average. The company has a market cap of $1.8B and remains unprofitable, with a trailing twelve-month EPS of -8.88 and revenue declining 100% year-to-date. The stock has a beta of 3.67, indicating high volatility. Three insiders have bought a total of $3.5M in shares over the last 90 days.
What To Watch
The company is scheduled to present the Phase 2 HNSCC results in a webcast on September 8, 2026, at 5:00 a.m. PT. Investors should monitor the coverage breadth and any follow-up data that may influence the stock’s trajectory ahead of the FDA BLA filing in April 2027.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
INBX by the numbers
Last: $120.88Session: +5.72%7 sessions: -0.33%Coverage: 9 stories / 8 sourcesAI sentiment: 68/100 (bullish)Mkt cap: $1.8B52w: $26.19 to $155.29
The headlines behind the move
4d agoSeeking AlphaBULLISH 63Product/PR
Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom
Inhibrx (INBX) updates: ozekibart & INBRX-106 show strong rare cancer and immuno-oncology data; FDA BLA due Apr 2027.
4d agoTipRanksBULLISH 73Product/PR
Inhibrx Biosciences reports strong Phase 2 INBRX-106 data
Inhibrx Biosciences Inc ( ($INBX) ) has provided an announcement. On September 8, 2026, Inhibrx Biosciences reported primary endpoint data from the randomized Phase...
4d agoSEC 8-KNEUTRAL 50General
Inhibrx Biosciences, Inc. (INBX) files 8-K
Filed: 2026-09-08 AccNo: 0002007919-26-000047 Size: 5 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
4d agoSeeking AlphaBULLISH 73Product/PR
Inhibrx cancer therapy outperforms Merck’s Keytruda in mid-stage trial
Inhibrx Biosciences (INBX) stock gains as cancer therapy INBRX-106 with Merck (MRK) Keytruda outperforms the blockbuster drug in a mid-stage trial. Read more here.
5d agoInvestorsHubBULLISH 67Product/PR
Inhibrx Shares Rise After Positive Phase 2 Head and Neck Cancer Data
Inhibrx shares rose 6% after Phase 2 data showed higher response rates for INBRX-106 plus pembrolizumab in head and neck cancer.
5d agoInvesting.com MarketsBULLISH 73Product/PR
Inhibrx stock jumps on positive cancer drug trial results
Inhibrx stock jumps on positive cancer drug trial results
5d agoThe FlyBULLISH 73Product/PR
Inhibrx’s INBRX-106 achieves clinical benefit in Phase 2 HNSCC study
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on INBX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier INBX move explainers: 2026-09-09 · 2026-09-08